Esketamine receives Breakthrough Therapy Designation from FDA for major depressive disorder with imminent risk for suicide
- Details
- Category: Johnson & Johnson
Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for esketamine, an investigational antidepressant medication, for the indication of major depressive disorder with imminent risk for suicide.
Amgen and Advaxis enter global cancer immunotherapies collaboration
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor.
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
- Details
- Category: Novartis
Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbourne, Australia on Aug 22, 2016. The Novartis Prizes for Immunology are awarded every three years for breakthrough contributions to the fields of basic and clinical immunology.
Pfizer announces publication of new analysis showing long-term therapy with VYNDAQEL (tafamidis) slowed progression of rare neurodegenerative disease
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5.5 years, showed
Vonvendi, the first and only recombinant treatment for adults affected by von Willebrand disease, launches in the USA
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPG), continuing on Baxalta's long-standing commitment to the bleeding disorder community, today announced the U.S. launch of VONVENDI [von Willebrand factor (Recombinant)], the only recombinant treatment for adults living with von Willebrand disease (VWD).
GSK and Verily to establish Galvani Bioelectronics - a new company dedicated to the development of bioelectronic medicines
- Details
- Category: GlaxoSmithKline
GSK (LSE/NYSE: GSK) has announced an agreement with Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, to form Galvani Bioelectronics to enable the research, development and commercialisation of bioelectronic medicines. GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.
Boehringer Ingelheim: Growth in all core businesses
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim reported currency-adjusted growth in all its core businesses in the first half of 2016. At the same time, the research-driven pharmaceutical company achieved key strategic milestones by signing contracts to exchange businesses with Sanofi and completing the internal restructuring of its human pharmaceuticals business.
More Pharma News ...
- Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
- Pfizer aims to become industry leader in gene therapy with acquisition of Bamboo Therapeutics, Inc.
- Bristol-Myers Squibb reports second quarter financial results
- Merck receives Breakthrough Therapy Designation from FDA and PRIME status from EMA for investigational Ebola Zaire vaccine (V920)
- Roche delivers continued growth in the first half of 2016
- The European Stroke Organisation and Boehringer Ingelheim launch the "Angels Initiative"
- Pfizer receives World Health Organization prequalification for multi-dose vial presentation of Prevenar 13®